Li Xinghui, Wu Yandi, Zhao Jingjing, Wang Haiping, Tan Jing, Yang Ming, Li Yuanlong, Deng Shijie, Gao Saifei, Li Hui, Yang Zhenyu, Yang Fengmin, Ma Jianxing, Cheng Jianding, Cai Weibin
Guangdong Engineering & Technology Research Center for Disease-Model Animals, Laboratory Animal Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, Guangdong, China.
Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, Guangdong, China.
Theranostics. 2020 Feb 3;10(6):2675-2695. doi: 10.7150/thno.40735. eCollection 2020.
: Little is known about the pathophysiological diversity of myocardial injury in type 2 diabetes mellitus (T2DM), but analyzing these differences is important for the accurate diagnosis and precise treatment of diabetic cardiomyopathy. This study aimed to elucidate the key cardiac pathophysiological differences in myocardial injury between obese and non-obese T2DM from mice to humans. : Obese and non-obese T2DM mouse models were successfully constructed and observed until systolic dysfunction occurred. Changes in cardiac structure, function, energy metabolism and oxidative stress were assessed by biochemical and pathological tests, echocardiography, free fatty acids (FFAs) uptake fluorescence imaging, transmission electron microscopy, . Key molecule changes were screened and verified by RNA sequencing, quantitative real-time polymerase chain reaction and western blotting. Further, 28 human heart samples of healthy population and T2DM patients were collected to observe the cardiac remodeling, energy metabolism and oxidative stress adaptations as measured by pathological and immunohistochemistry tests. : Obese T2DM mice exhibited more severe cardiac structure remodeling and earlier systolic dysfunction than non-obese mice. Moreover, obese T2DM mice exhibited severe and persistent myocardial lipotoxicity, mainly manifested by increased FFAs uptake, accumulation of lipid droplets and glycogen, accompanied by continuous activation of the peroxisome proliferator activated receptor alpha (PPARα) pathway and phosphorylated glycogen synthase kinase 3 beta (p-GSK-3β), and sustained inhibition of glucose transport protein 4 (GLUT4) and adipose triglyceride lipase (ATGL), whereas non-obese mice showed no myocardial lipotoxicity characteristics at systolic dysfunction stage, accompanied by the restored PPARα pathway and GLUT4, sustained inhibition of p-GSK-3β and activation of ATGL. Additionally, both obese and non-obese T2DM mice showed significant accumulation of reactive oxygen species (ROS) when systolic dysfunction occurred, but the NF-E2-related factor 2 (Nrf2) pathway was significantly activated in obese mice, while was significantly inhibited in non-obese mice. Furthermore, the key differences found in animals were reliably verified in human samples. : Myocardial injury in obese and non-obese T2DM may represent two different types of complications. Obese T2DM individuals, compared to non-obese individuals, are more prone to develop cardiac systolic dysfunction due to severe and persistent myocardial lipotoxicity. Additionally, anti-oxidative dysfunction may be a key factor leading to myocardial injury in non-obese T2DM.
关于2型糖尿病(T2DM)中心肌损伤的病理生理多样性,人们所知甚少,但分析这些差异对于糖尿病性心肌病的准确诊断和精准治疗至关重要。本研究旨在阐明从小鼠到人类,肥胖与非肥胖T2DM患者心肌损伤在心脏病理生理方面的关键差异。
成功构建了肥胖和非肥胖T2DM小鼠模型,并观察至出现收缩功能障碍。通过生化和病理检测、超声心动图、游离脂肪酸(FFA)摄取荧光成像、透射电子显微镜等评估心脏结构、功能、能量代谢和氧化应激的变化。通过RNA测序、定量实时聚合酶链反应和蛋白质免疫印迹筛选并验证关键分子变化。此外,收集了28例健康人群和T2DM患者的人类心脏样本,通过病理和免疫组化检测观察心脏重塑、能量代谢和氧化应激适应情况。
肥胖T2DM小鼠比非肥胖小鼠表现出更严重的心脏结构重塑和更早的收缩功能障碍。此外,肥胖T2DM小鼠表现出严重且持续的心肌脂毒性,主要表现为FFA摄取增加、脂滴和糖原积累,伴有过氧化物酶体增殖物激活受体α(PPARα)途径和磷酸化糖原合酶激酶3β(p-GSK-3β)的持续激活,以及葡萄糖转运蛋白4(GLUT4)和脂肪甘油三酯脂肪酶(ATGL)的持续抑制,而非肥胖小鼠在收缩功能障碍阶段未表现出心肌脂毒性特征,伴有PPARα途径和GLUT4的恢复、p-GSK-3β的持续抑制和ATGL的激活。此外,肥胖和非肥胖T2DM小鼠在出现收缩功能障碍时均表现出活性氧(ROS)的显著积累,但NF-E2相关因子2(Nrf2)途径在肥胖小鼠中显著激活,而在非肥胖小鼠中显著抑制。此外,在动物中发现的关键差异在人类样本中得到了可靠验证。
肥胖和非肥胖T2DM中的心肌损伤可能代表两种不同类型的并发症。与非肥胖个体相比,肥胖T2DM个体由于严重且持续的心肌脂毒性更容易发生心脏收缩功能障碍。此外,抗氧化功能障碍可能是导致非肥胖T2DM中心肌损伤的关键因素。